Search Within

Paul M Dodd

Formats
  1. Journal Article (9)
  2. Meeting Abstract (3)
  3. Book Section (2)
Groups
  1. Department of Medicine (12)
  2. Genitourinary Oncology Service (12)
  3. Solid Tumor Oncology Division (12)
  4. Surgery (10)
  5. Urology (10)
  6. Nursing (4)
People
  1. Dean Bajorin (12)
  2. Harry Herr (10)
  3. John McCaffrey (10)
  4. Madhu Mazumdar (10)
  5. Geralyn Higgins (9)
  6. Howard Scher (6)

More People

Years
  1. 2001 (2)
  2. 2000 (5)
  3. 1999 (4)
  4. 1998 (3)
Publications
  1. Journal of Clinical Oncology (3)
  2. Cancer (2)
  3. Cancer Investigation (2)
  4. Clinical Oncology (2)
  5. Current Opinion in Urology (1)
  6. Investigational New Drugs (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (3)
  2. American Cancer Society (2)
  3. Informa Healthcare (2)
  4. Wiley Blackwell (2)
  5. Elsevier Inc. (1)
  6. Elsevier Science, Inc. (1)

More Publishers

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Urologic and male genital cancer - Testicular cancer
    Book Section

    Dodd, P. M.; Kelly, W. K.
    In Lenhard, R. J. Jr; Osteen, R. T.; Gansler, T. (Eds.) Clinical Oncology (2001)

    Fulltext@MSK | Save
  • Urologic and male genital cancer - Prostate cancer
    Book Section

    Kelly, W. K.; Dodd, P. M.
    In Lenhard, R. J. Jr; Osteen, R. T.; Gansler, T. (Eds.) Clinical Oncology (2001)

    Fulltext@MSK | Save
  • Ifosfamide, paclitaxel, and cisplatin (ITP) in urothelial cancer: The Memorial Sloan-Kettering Cancer Center experience with ITP as a single regimen and preceded by doxorubicin and gemcitabine (AG) in a dose-dense sequenced approach
    Meeting Abstract

    Bajorin, D. F.; McCaffrey, J. A.; Dodd, P.; Hilton, S.; Mazumdar, M.; Donat, S.; Herr, H.; Higgins, G.
    Cancer Investigation (2000)

    Fulltext@MSK | Save
  • Phase I evaluation of sequential doxorubicin + gemcitabine then ifosfamide + paclitaxel + cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract
    Journal Article

    Dodd, P. M.; Mccaffrey, J. A.; Hilton, S.; Mazumdar, M.; Herr, H.; Kelly, W. K.; Icasiano, E.; Boyle, M. G.; Bajorin, D. F.
    Journal of Clinical Oncology (2000)

    Fulltext@MSK | Save
  • Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma
    Journal Article

    Dodd, P. M.; Mccaffrey, J. A.; Mazumdar, M.; Icasiano, E.; Higgins, G.; Herr, H.; Bajorin, D. F.
    Investigational New Drugs (2000)

    Fulltext@MSK | Save
  • Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer
    Journal Article

    Dodd, P. M.; Mccaffrey, J. A.; Mazumdar, M.; Scher, H.; Higgins, G.; Boyle, M. G.; Herr, H.; Bajorin, D. F.
    Cancer Investigation (2000)

    Fulltext@MSK | Save
  • Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules
    Journal Article

    Bajorin, D. F.; Mccaffrey, J. A.; Dodd, P. M.; Hilton, S.; Mazumdar, M.; Kelly, W. K.; Herr, H.; Scher, H. I.; Icasiano, E.; Higgins, G.
    Cancer (2000)

    Fulltext@MSK | Save
  • Transitional cell carcinoma (TCC): Status of investigations with ifosfamide, paclitaxel, and cisplatin (ITP)
    Meeting Abstract

    Bajorin, D. F.; Dodd, P. M.; McCaffrey, J. A.; Hilton, S.; Mazumdar, M.; Donat, S.; Herr, H.; Icasiano, E.; Higgins, G.
    Seminars in Oncology (1999)

    Fulltext@MSK | Save
  • Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
    Journal Article

    Bajorin, D. F.; Dodd, P. M.; Mazumdar, M.; Fazzari, M.; McCaffrey, J. A.; Scher, H. I.; Herr, H.; Higgins, G.; Boyle, M. G.
    Journal of Clinical Oncology (1999)

    Fulltext@MSK | Save
  • Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
    Journal Article

    Dodd, P. M.; McCaffrey, J. A.; Herr, H.; Mazumdar, M.; Bacik, J.; Higgins, G.; Boyle, M. G.; Scher, H. I.; Bajorin, D. F.
    Journal of Clinical Oncology (1999)

    Fulltext@MSK | Save